FDA's CMC Pilot Program Moves Forward - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA's CMC Pilot Program Moves Forward


ePT--the Electronic Newsletter of Pharmaceutical Technology

Washington, DC (Sept. 12)—The Office of New Drug Quality Assessment (ONDQA) in the Center for Drug Evaluation and Research (CDER) has approved one new drug application (NDA) under its CMC Pilot Program and has two more applications under review. The pilot was established last year to provide an opportunity for FDA and industry to explore strategies for including quality-by-design (QbD) principles and process analytical technology approaches in regulatory submissions, explained ONDQA deputy director Chi-wan Chen at the PDA-FDA Joint Regulatory Conference.

By working with companies on specific applications, FDA hopes to better define what constitutes a QbD-based submission and a science-based risk assessment. Two other pilot applications, including one supplement, are under review, and manufacturers have identified eight future submissions that will come into the agency during the next year and a half under the program. FDA plans to use the experience gained under the pilot to develop further guidance on QbD and its science- and risk-based approach to CMC review.

All pilot NDAs provide more scientific information on formulation and product development than typical applications in order to show a full understanding of the production process, Chen explained. Such relevant scientific information is useful to ONDQA in conducting a CMC review and in justifying future regulatory flexibility. This scientific information is included in an expanded Pharmaceutical Development section (P. 2 of the common technical document). A comprehensive Quality Overall Summary provides a broad overview of how this information is addressed in the document.

Regulatory flexibility is the expected reward for industry pilot participants. A manufacturer that demonstrates full knowledge and understanding of critical quality attributes, process development, and design space may be able to substitute in-process testing for end-product testing and report post-approval changes in an annual report. FDA may spell out such benefits in a “CMC regulatory agreement.” If the manufacturer defines critical quality attributes and design space for making planned changes, FDA may agree to future regulatory flexibility based on adherence to stated criteria. Such an agreement has been proposed in one application so far, explained Chen, and it is “being explored” by FDA officials.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here